Mira Pharmaceuticals (MIRA) Receivables - Net (2023 - 2024)
Mira Pharmaceuticals (MIRA) posted Receivables - Net of $5000.0 for Q4 2024, little changed sequentially from $5000.0 in Q4 2023, and little changed YoY from $5000.0 in Q1 2024.
Mira Pharmaceuticals (MIRA) Receivables - Net (2023 - 2024) Analysis & Trends
Mira Pharmaceuticals has reported Receivables - Net for 2 years, with the latest figure at $5000.0 in Q4 2024.
- Quarterly Receivables - Net changed 0.0% year-over-year to $5000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $5000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $5000.0, changed 0.0% from the prior year.
- Receivables - Net steadied at $5000.0 in Q4 2024 per MIRA's latest filing, from $5000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $5000.0 in Q4 2023 and troughed at $5000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 5,000.00 |
| Dec 31, 2023 | 5,000.00 |